Candin Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to need for immune competency assessment, reliance on dth testing methods, hospital diagnostic expansion, increased immunosuppressive therapies, growth of clinical immunology.

The growth in the forecast period can be attributed to rising immunodeficiency prevalence, expansion of immune monitoring protocols, growth in diagnostic testing volumes, improved clinical awareness, healthcare infrastructure development. Major trends in the forecast period include growing use of immune function diagnostic tests, expansion of cell mediated immunity assessment, rising demand for diagnostic skin testing, increased focus on immunosuppressive disorder detection, strengthening of hospital based diagnostic services.

The increasing prevalence of tuberculosis is expected to drive the growth of the candin market in the coming years. Tuberculosis (TB) is a contagious infectious disease caused by the bacterium Mycobacterium tuberculosis, primarily affecting the lungs but capable of spreading to other parts of the body, and transmitted through airborne droplets from infected individuals. The rise in TB cases is fueled by factors such as untreated or undiagnosed cases, drug-resistant TB strains, gaps in healthcare access, population displacement, and co-infections like HIV, which weaken immunity. Candin supports TB management by serving as a control in skin testing to evaluate cell-mediated immunity, helping distinguish immune responses caused by Mycobacterium tuberculosis from nonspecific anergic reactions in individuals with suspected TB or compromised immune function. For example, in November 2024, the Centers for Disease Control and Prevention (CDC), a US-based national public health organization, reported 9,633 TB cases in the United States in 2023, marking a 15.6% increase from 8,332 cases in 2022. Therefore, the increasing prevalence of tuberculosis is driving the growth of the candin market.

The growing demand for personalized medicine is also expected to drive the expansion of the candin market. Personalized medicine tailors treatment and healthcare practices to individual patient characteristics, including genetics, lifestyle, and environment. The rise of personalized medicine is supported by advancements in genomics, AI, and biotechnology, enabling more targeted and effective treatments, while precision diagnostics and therapies continue to broaden its adoption. Candin supports personalized medicine by providing diagnostic tools that allow healthcare providers to tailor treatments based on individual patient profiles, such as genetic factors and immune responses, enhancing treatment efficacy and minimizing adverse effects. For example, in February 2024, the Personalized Medicine Coalition, a US-based healthcare organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the candin market.

A key trend in the candin market is the development of strategic partnerships to offer non-invasive, cost-effective, and efficient treatment options. Strategic partnerships involve collaborative agreements between organizations to leverage each other’s expertise, resources, and strengths for mutual benefit, often sharing risks, rewards, and responsibilities in areas like product development, market expansion, or innovation. For instance, in May 2023, Nielsen BioSciences Inc., a US-based pharmaceutical company, entered into a licensing agreement with Maruho Co. Ltd., a Japan-based pharmaceutical company, to sell Candin in Japan for the treatment of verruca vulgaris. Under this agreement, Maruho made a significant upfront payment to Nielsen and assumed all costs related to further development and regulatory activities for candin a diagnostic skin test aimed at treating common warts.

Major companies operating in the candin market are Nielsen BioSciences Inc.

North America was the largest region in the candin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the candin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the candin market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the candin market by increasing costs associated with imported diagnostic reagents, antigen preparation materials, and sterile packaging supplies. These impacts have affected hospital and clinic procurement, especially in regions dependent on international diagnostic imports. Asia pacific and latin america show higher sensitivity due to growing testing demand. However, tariffs have supported local reagent production, reduced long term costs, and improved diagnostic supply stability.

The candin market research report is one of a series of new reports that provides candin market statistics, including candin industry global market size, regional shares, competitors with a candin market share, detailed candin market segments, market trends and opportunities, and any further data you may need to thrive in the candin industry. This candin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Candin is a purified extract from the Candida albicans organism, commonly used as a diagnostic skin test antigen to assess cell-mediated immunity. It works by triggering a delayed-type hypersensitivity (DTH) response in individuals with a functioning immune system, making it useful for evaluating immune competency. Candin is typically employed in healthcare settings to detect conditions such as anergy in patients suspected of having immunosuppressive disorders.

The primary indications for candin are candidiasis and thrush. Candidiasis is a fungal infection caused by the overgrowth of Candida species, often affecting the mouth, throat, skin, and genital areas. Candin is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used by hospitals, clinics, ambulatory care centers, and home care providers.

The candin market consists of sales of diagnostic skin test antigens, immunotherapy products, vaccines, serology kits and recombinant antigens. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.